摘要
Objective: To observe the clinical results of combination therapy for multiple myeloma by arsenic trioxide, melphalan, vitamin C and dexamethasone. Methods: 18 cases with multiple myeloma, 12 males and 6 females were given the treatment including arsenic trioxide, melphalan, vitamin C and dexamethasone combination therapy; the dosage of arsenic trioxide 10 mg, d1-5, d8-12; vitamin C 1.0 g, d1-5, d8-12; dexamethasone 20 mg, d1-4, d8-11; melphalan 2 mg, tid, d1-12. Complete response(CR), partial response(PR), minimal response(MR), no change(NC) were observed. Results: The CR were 16.7 %(3/18), PR were 77.7 %(14/18), MR were 5.6 %(1/18). Conclusion: Combinational arsenic trioxide, melphalan, vitamin C and dexamethasone is an effective therapy with less side effects, which can be considered for treating the initial or relapsed or refractory MM.
| 源语言 | 英语 |
|---|---|
| 页(从-至) | 351-352+355 |
| 期刊 | Journal of Leukemia and Lymphoma |
| 卷 | 17 |
| 期 | 5 |
| 出版状态 | 已出版 - 25 10月 2008 |
联合国可持续发展目标
此成果有助于实现下列可持续发展目标:
-
可持续发展目标 3 良好健康与福祉
学术指纹
探究 'TAD regimen with melphalan to treat 18 cases of multiple myeloma' 的科研主题。它们共同构成独一无二的学术指纹。引用此
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver